The World Health Organization has reported the incidence rate of mantle cell lymphoma globally as 0.5 cases per 100,000 people. Mantle cell lymphoma possess an aggressive disease etiology that usually commences with the enlargement of lymph node and progress to metastasis to other organs such as bone marrow, gastrointestinal tract, and liver. Mantle cell lymphoma is resistant to chemotherapy drug treatment and so a targeted treatment approach has been adopted with promising drugs in the product pipeline with better drug efficacy and safety e.g. Zydelig, Gazyva, Abemaciclib and KTE-C19.
To understand the drug regimen used for the treatment of mantle cell lymphoma the drugs segmented on the basis of mechanism of action are Bruton's Tyrosine Kinase Blocker (ibrutinib), Angiogenesis Inhibitor (lenalidomide), CD20 Antigen Inhibitor (rituximab), mTOR Protein Inhibitor (temsirolimus) and Proteasome Inhibitors (bortezomib). A brief description regarding the market size and forecast is available for the above segment.
To understand the performance of drugs employed for the treatment of mantle cell lymphoma in the regional segments their respective major countries has been considered in the segment.
Rest of Europe
Rest of Asia Pacific
Rest of LATAM
Middle East and Africa
Rest of Middle East and Africa
Country cross sectional market estimate and forecast for the geography segment has been included in the scope of the report.
The most important aspect is to understand that a promising pipeline will result in competition among the prominent players to have a significant hold on the mantle cell. In order to understand the competitive environment in the development of drug for the treatment of mantle cell lymphoma we need to cater competitive landscape. Latest merger or acquisition and purchase of promising drug molecules are mentioned in the company profile section. The major players in global mantle cell lymphoma treatment market are Celgene Corporation Abbvie, Inc., Astellas Pharma, Inc., Biogen, Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Amgen, Inc., Gilead Sciences, Inc. Johnson and Johnson and F.Hoffman La Roche Ltd.
Simulation Type Segmentation Investigation
Based on sales simulation types, global mannequin-based simulation market is segmented as:
Simulation-based medical training efficiently offers training to medical professionals for performing critical procedures on an interactive platform. This also assists surgeons and medical staff in improving clinical skills, emergency care delivery and augment safety outcomes. Patient simulation solutions offer high-fidelity equipment with features such as breathing pattern, sounds, pulse measurement, blood pressure monitoring, EKG and others. This market is driven by ethical sensitivity about patient subjects, and growing concerns on patient safety.
High-risk clinical departments such as intensive care, emergency response, anesthesia, neonatal care, and cath labs would most prominently benefit from adoption of mannequin-based simulation for training and education of healthcare personnel. This market may experience challenges in terms of restrained government funds.
Based on the type of end-users, the global mannequin-based simulation market is categorized into:
1. Academics 2. Hospitals 3. Defense and Military
Mannequin-based simulation finds the widest use in academics. Simulated medical training offers advantages such as safe training modules, hands-on education in interactive settings, and extensive training for emergency response. Challenges such as patient safety concerns are efficiently overcome through mannequin-based simulation tools such as high fidelity mannequins, patient safety virtual reality simulation and others. These solutions are being increasingly used in settings such as hospital rooms, emergency settings, and simulation facilities as training solutions and have demonstrated impressive results. Underutilization of simulation technologies due to complexity in assembly and operation had been a hindrance for growth in the past; however, it is being overcome by introduction of automated instruction and better user interfaces.
Based on geographical segmentation, the global mannequin-based simulation market is studied for:
Middle East and Africa
North America and Europe are the largest regional markets for mannequin-based simulation. Growth in adoption of simulation technologies and rise in demand for minimally invasive procedures are the prime factors driving the mannequin-based simulation market in these regions. In addition, success in use of mannequin-based simulation in delivering patient safety is a strong driving factor in the developed markets. On the other hand, limits on funding in such activities by siphoning the resources to other areas such as technological development in surgical procedures may hold back the growth of this market. Asia-Pacific and Latin America markets will undergo rapid growth during the forecast period. The demand for simulation solutions for training and education purposes will be high in these regions.
Key Topics Covered:
Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Mantle Cell Lymphoma Treatment Market: Dynamics and Future Outlook 3.1. Market Overview 3.2. Drivers 3.3. Challenges 3.4. Opportunities 3.5. Attractive Investment Proposition, by Geography 3.6. Top 3 Countries: Global Mantle Cell Lymphoma Treatment Market, 2019-2029 (US$ Mn) 3.7. Competitive Landscape: Global Mantle Cell Lymphoma Treatment Market, by Key Players, 2019-2029 (US$ Mn)
Chapter 4. Global Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2019 - 2029 (US$ Mn) 4.1. Overview 4.2. Attractive Investment Proposition: Global Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2020 4.3. Bruton's Tyrosine Kinase Blocker (Ibrutinib) 4.4. Angiogenesis Inhibitor (Lenalidomide) 4.5. CD20 Antigen Inhibitor (Rituximab) 4.6. mTOR Protein Inhibitor (Temsirolimus) 4.7. Proteasome Inhibitors (Bortezomib) 4.8. Phase III Drug 4.9. Tabular Representation of Phase II and I Drugs
Chapter 5. Global Mantle Cell Lymphoma Treatment Market, by Geography, 2019 - 2029 (US$ Mn) 5.1. Overview 5.2. North America Mantle Cell Lymphoma Treatment Market Analysis, 2019 - 2029 5.3. Europe Mantle Cell Lymphoma Treatment Market Analysis, 2019 - 2029 5.4. Asia Pacific Mantle Cell Lymphoma Treatment Market Analysis, 2019 - 2029 5.5. Latin America Mantle Cell Lymphoma Treatment Market Analysis, 2019 - 2029 5.6. Middle East & Africa Mantle Cell Lymphoma Treatment Market Analysis, 2019 - 2029
Chapter 6. Company Profiles 6.1. Abbvie, Inc. 6.2. Amgen, Inc. 6.3. Astellas Pharma, Inc. 6.4. Biogen, Inc. 6.5. Bayer AG 6.6. Bristol-Myers Squibb Company 6.7. Celgene Corporation 6.8. Eli Lilly and Company 6.9. GlaxoSmithKline Plc 6.10. Gilead Sciences, Inc. 6.11. Johnson and Johnson 6.12. F.Hoffman La Roche Ltd.